Gilead Sciences and Xilio Therapeutics Forge Path in Cancer Treatment with Tumor-Activated IL-12 Program.
Therapeutics Company Announces Licensing Agreement With Gilead Sciences
Therapeutics Company Announces Licensing…
Therapeutics Company Announces Licensing Agreement With Gilead Sciences
Gilead Sciences and Xilio Therapeutics Forge Path in Cancer Treatment with Tumor-Activated IL-12 Program.